GALNT2 and non-small cell lung carcinoma: Furthermore, LY294002 (PI3K/Akt inhibitor, 10 μmol/L) or PD98059 (MAPK/ERK inhibitor, 10 μmol/L) could attenuate the promotive effects of GALNT2 on NSCLC cell proliferation, migration, and invasion (Fig. 8E–G).